Analysts Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Price Target at $43.17

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned a consensus rating of “Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $43.17.

Several research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Thursday, October 31st. Jefferies Financial Group started coverage on Oruka Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Wedbush assumed coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Lifesci Capital started coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target for the company. Finally, Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 17th.

Oruka Therapeutics Price Performance

ORKA stock opened at $26.68 on Thursday. The stock’s 50 day moving average is $26.85. The firm has a market capitalization of $32.28 million, a P/E ratio of -4.44 and a beta of 0.87. Oruka Therapeutics has a twelve month low of $18.72 and a twelve month high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.